Eli Lilly and Pfizer’s nonopioid NGF inhibitor tanezumab beat out placebo in a phase 3 study of patients with chronic lower back pain.
Aradigm’s bid to get an inhaled antibiotic to market seems at an end, with its assets up for sale and the jobs of two primary executives terminated.
The actions are part of the biotech’s ongoing efforts to seek a way out of its R&D-triggered troubles.
Joe Anderson stepped down as CEO in September to take up the chief investment officer position but now finds himself back in charge of the company.
In a pivotal phase 3 study, Intercept Pharmaceuticals' obeticholic acid improved liver fibrosis without any worsening of NASH after 18 months.
A Duke lab at the center of a research pact with Sarepta is reporting promising results from a trial of CRISPR gene editing in mouse models of DMD.
TCR2 Therapeutics has priced its IPO at the midpoint of the target range. The offering stands to net TCR2 $67 million.
A protein originally developed to boost the power of T cells in treating cancer protected normal mice from developing cancer in the first place.
The deal, which was signed into law on Friday by President Trump, includes the biggest increase in FDA funding in several years.
Sanofi's CMO takes on chief digital officer role; Parexel nabs four high-profile FDA staffers; and Nimbus poaches Janssen's discovery head as CSO.